• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Viemed Healthcare Inc.

    8/12/24 5:20:48 PM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care
    Get the next $VMD alert in real time by email
    S-8 1 forms-8081224.htm S-8 Document

    As filed with the Securities and Exchange Commission on August 12, 2024.
    Registration No. 333-

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
                                                                                                 

    FORM S-8
    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
                                                                                                 

    VIEMED HEALTHCARE, INC.
    (Exact name of registrant as specified in its charter)
                                                                                                     
    British Columbia, CanadaN/A
    (State or Other Jurisdiction
    of Incorporation or Organization)
    (I.R.S. Employer
    Identification No.)
    625 E. Kaliste Saloom Rd.
    Lafayette, Louisiana 70508
    (Address of Principal Executive Offices) (Zip Code)
                                                                                                 
    VIEMED HEALTHCARE, INC. 2024 LONG TERM INCENTIVE PLAN
    (Full Title of the Plan)

    Name, Address and TelephoneCopy of Communications to:
    Number of Agent for Service:
    Trae FitzgeraldE. James Cowen
    Chief Financial OfficerPorter Hedges LLP
    Viemed Healthcare, Inc.
    1000 Main Street, 36th Floor
    625 E. Kaliste Saloom Rd.Houston, Texas 77002-6336
    Lafayette, Louisiana 70508(713) 226-6000
    (337) 504-3802
                                                                                                     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
    Large accelerated filer ☐
    Accelerated filer ☒
    Non-accelerated filer ☐ (Do not check if a smaller reporting company)
    Smaller reporting company ☐
    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐






    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
        Viemed Healthcare, Inc. (the “Company”) prepared this Registration Statement in accordance with the requirements of Form S-8 under the Securities Act of 1933, as amended (the “Securities Act”), to register an aggregate of 7,800,000 common shares, no par value, of the Company (the “common shares”) that may be issued pursuant to the Viemed Healthcare, Inc. 2024 Long Term Incentive Plan (the “Plan”). The documents containing the information specified in Part I of this Registration Statement will be sent or given to participants in the Plan, as specified by Rule 428(b)(1) promulgated under the Securities Act. Such documents need not be filed with the Securities and Exchange Commission (the “Commission”) either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 promulgated under the Securities Act. These documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute a prospectus that meets the requirement of Section 10(a) of the Securities Act.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.
        The following documents, which have previously been filed by the Company with the Commission under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated herein by reference:

    •The Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Commission on March 6, 2024, and portions of the Company's Definitive Proxy Statement on Schedule 14A filed with the Commission on April 26, 2024, incorporated by reference therein (File No. 001-38973);

    •The Company’s Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2024 and June 30, 2024, filed with the Commission on May 6, 2024 and August 7, 2024, respectively (File No. 001-38973);

    •The Company’s Current Reports on Form 8-K, filed with the Commission on May 29, 2024 and June 6, 2024 (File No. 001-38973) (excluding any information furnished pursuant to Item 2.02 or Item 7.01, or any corresponding information furnished under Item 9.01, of any such Current Report on Form 8-K); and

    •The description of the common shares of the Company contained in the Company’s registration statement on Form 10, filed with the Commission on July 10, 2019, as amended by Amendment No. 1 to Form 10, filed with the Commission on August 1, 2019 (File No. 001-38973), as updated by the description of the common shares of the Company filed as Exhibit 4.1 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Commission on March 6, 2024 (File No. 001-38973), including any amendment or report filed for purposes of updating such description.

        In addition, all documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (excluding any information furnished pursuant to Item 2.02 or Item 7.01, or any corresponding information furnished under Item 9.01, on any Current Report on Form 8-K) prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is or is deemed to be incorporated by reference herein, as the case may be, modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.





    Item 4. Description of Securities.
        
    Not applicable.

    Item 5. Interests of Named Experts and Counsel.

        The validity of the issuance of the common shares will be passed upon for the Company by DLA Piper (Canada) LLP. As of August 7, 2024, certain attorneys at DLA Piper (Canada) LLP owned 2,200 common shares of the Company.

    Item 6. Indemnification of Officers and Directors.

    The Business Corporations Act (British Columbia) (the “Business Corporations Act”) provides that:

    1.The Company may indemnify an individual who: (i) is or was a director, alternate director or officer of the Company; (ii) is or was a director, alternate director or officer of another corporation: (A) at a time when such other corporation is or was an affiliate of the Company; or (B) at the request of the Company; or (iii) at the request of the Company, is or was, or holds or held a position equivalent to that of, a director, alternate director or officer of a partnership, trust, joint venture or other unincorporated entity, and his or her heirs and personal or other legal representatives of that individual (each such person referred to herein as an “eligible party.”)

    2.Such indemnity may provide for indemnification against any judgment, penalty, fine or settlement paid in respect of a proceeding in which such individual, by reason being or having been an eligible party is or may be joined as a party, or is or may be liable for provided, (a) he or she acted honestly and in good faith with a view to the best interests of the Company; and (b) in the case of a criminal or administrative action or proceeding that is enforced by a monetary penalty, he or she had reasonable grounds for believing that his or her conduct was lawful.

    3.If the Company declines to provide indemnification, a court may, on the application of the Company or an eligible party: (i) order the Company to indemnify an eligible party in the manner provided under (1); (ii) order the Company to pay some or all of the expenses incurred by an eligible party in respect of an eligible proceeding; (iii) order the enforcement of, or any payment under, an agreement of indemnification entered into by the Company; (iv) order the Company to pay some or all of the expenses actually and reasonably incurred by any person in obtaining an order for indemnification under this item (3); or (v) make any other order the court considers appropriate.

    4.An eligible party is entitled to indemnity from the Company in respect of all costs, charges and expenses actually and reasonably incurred by him or her in connection with the defense of any proceeding to which he or she is made a party by reason of being an eligible party, if the person seeking indemnity, (a) is wholly successful, on the merits or otherwise, in the outcome of the proceeding or is substantially successful on the merits in the outcome of the proceeding, and (b) fulfills the conditions set out in clauses (2)(a) and (b) above.

    5.The Company may purchase and maintain insurance for the benefit of an eligible party against any liability that may be incurred by reason of the eligible party being or having been a director or officer of, or holding or having held a position equivalent to that of a director or officer of, the Company or an associated corporation.

        The Company’s Articles provide that the Company must indemnify, to the extent allowed under the BCBCA, each eligible party against all eligible penalties to which such person is or may be liable, and the Company must, after the final disposition of an eligible proceeding, pay the expenses actually and reasonably incurred by such person in respect of that proceeding. The Articles further provide that the Company may advance expenses to an eligible party to the extent permitted by and in accordance with the BCBCA. The Articles also authorize the Company to purchase and maintain directors’ and officers’ liability insurance.

    The Company maintains directors’ and officers’ liability insurance for its officers and directors.

    Each director and officer is also a party to an indemnification agreement with the Company, pursuant to which the Company has agreed, to the fullest extent not prohibited by law and promptly upon demand, to indemnify and hold harmless such director or officer, his or her heirs and legal representatives from and against (i) all costs, charges and expenses incurred by such director or officer in respect of any claim, demand, suit, action, proceeding or investigation in which such director or officer is involved or is subject by reason of being or having been a director or officer and (ii) all liabilities, damages, costs, charges and expenses whatsoever that the director or officer may sustain or incur as a result of serving as a director or officer in respect of any act, matter, deed or thing whatsoever made, done, committed, permitted or



    acquiesced in by such director or officer in his or her capacity as a director or officer, whether before or after the effective date of such indemnification agreement.

    Item 7. Exemption from Registration Claimed.

        Not applicable.

    Item 8. Exhibits.

        See Index to Exhibits, attached hereto, which Index to Exhibits is hereby incorporated into this Item 8.

    Item 9. Undertakings.

        (a) The Company hereby undertakes:

            (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

                (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement; and

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement.

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Company pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    (b) The Company hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Company’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Company pursuant to the foregoing provisions, or otherwise, the Company has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Company of expenses incurred or paid by a director, officer or controlling person of the Company in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Company will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.




    SIGNATURES

        Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Lafayette, State of Louisiana, on this 12th  day of August, 2024.
    VIEMED HEALTHCARE, INC.
    By:/s/ Trae Fitzgerald
    Trae Fitzgerald
    Chief Financial Officer

    POWER OF ATTORNEY

        KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Casey Hoyt, W. Todd Zehnder and Trae Fitzgerald, and each of them, either of whom may act without joinder of the other, his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any or all pre- and post-effective amendments and supplements to this registration statement, and to file the same, or cause to be filed the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto such attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and each of them, or the substitute or substitutes of either of them, may lawfully do or cause to be done by virtue hereof.

        Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the date indicated.
    SignatureTitleDate
    /s/ Casey HoytChief Executive Officer and DirectorAugust 12, 2024
    Casey Hoyt(Principal Executive Officer)
    /s/ Trae FitzgeraldChief Financial OfficerAugust 12, 2024
    Trae Fitzgerald(Principal Financial Officer and Accounting Officer)
    /s/ W. Todd ZehnderChief Operating Officer and DirectorAugust 12, 2024
    W. Todd Zehnder
    /s/ Randy DobbsChairman of the BoardAugust 12, 2024
    Randy Dobbs
    /s/ Dr. William FrazierDirector and Chief Medical OfficerAugust 12, 2024
    Dr. William Frazier
    /s/ Bruce GreensteinDirectorAugust 12, 2024
    Bruce Greenstein
    /s/ Sabrina HeltzDirectorAugust 12, 2024
    Sabrina Heltz
    /s/ Nitin KaushalDirectorAugust 12, 2024
    Nitin Kaushal
    /s/ Timothy SmokoffDirectorAugust 12, 2024
    Timothy Smokoff




    INDEX TO EXHIBITS
    Exhibit
    Number
    Description
    4.1
    Viemed Healthcare, Inc. 2024 Long Term Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Commission on June 6, 2024).
    *5.1
    Opinion of DLA Piper (Canada) LLP.
    *23.1
    Consent of Ernst & Young LLP.
    *23.3
    Consent of DLA Piper (Canada) LLP (included in Exhibit 5.1).
    *24.1
    Power of Attorney (included on signature page of this registration statement).
    *107.1
    Calculation of Filing Fee Tables
    *Filed herewith.


    Get the next $VMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VMD

    DatePrice TargetRatingAnalyst
    11/3/2021$13.00 → $9.00Outperform
    RBC Capital
    More analyst ratings

    $VMD
    SEC Filings

    View All

    Viemed Healthcare Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - VIEMED HEALTHCARE, INC. (0001729149) (Filer)

    11/7/25 4:02:17 PM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 10-Q filed by Viemed Healthcare Inc.

    10-Q - VIEMED HEALTHCARE, INC. (0001729149) (Filer)

    11/5/25 4:40:54 PM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    Viemed Healthcare Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - VIEMED HEALTHCARE, INC. (0001729149) (Filer)

    11/5/25 4:38:29 PM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    $VMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $VMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Viemed Healthcare Announces Share Repurchase Program

    LAFAYETTE, La., June 09, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader of in-home, technology-enabled post-acute respiratory care, today announced that its Board of Directors has authorized a share repurchase program, effective through June 2026. Under the share repurchase program, Viemed may purchase up to 1,976,441 common shares of the Company ("the Common Shares") from time to time in accordance with applicable securities laws, representing approximately 5% of the total issued and outstanding Common Shares as of March 31, 2025. The Company intends to repurchase Common Shares through open market purchases, block purchases o

    6/9/25 8:00:00 AM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    Viemed Healthcare to Present and Host 1x1 Investor Meetings at the 15th Annual East Coast Ideas Investor Conference on June 11th in New York

    LAFAYETTE, La., June 03, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, today announced it will present at the East Coast IDEAS Investor Conference on Wednesday June 11, 2025 at The Westin Times Square in New York, NY. Viemed's presentation is scheduled to begin at 11:30am ET. The presentation is webcast and can be accessed through the conference host's main website: https://www.threepartadvisors.com/east-coast and in the investor relations section of the Company's website: http://viemed.com/investors. ABOUT VIEMED HEALTHCARE, INC. Viemed is an

    6/3/25 8:00:00 AM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    Viemed Healthcare Announces First Quarter 2025 Financial Results

    LAFAYETTE, La., May 07, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three months ended March 31, 2025, and updated guidance for the full year ending December 31, 2025. Operational highlights (all dollar amounts are USD): Net revenues for the quarter ended March 31, 2025 were $59.1 million, representing an increase of $8.5 million, or 17%, over net revenues reported for the comparable quarter ended March 31, 2024. Net income attributable to Viemed for t

    5/7/25 4:45:00 PM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    RBC Capital reiterated coverage on Viemed Healthcare with a new price target

    RBC Capital reiterated coverage of Viemed Healthcare with a rating of Outperform and set a new price target of $9.00 from $13.00 previously

    11/3/21 9:01:34 AM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    Royal Bank of Canada initiated coverage on Viemed Healthcare with a new price target

    Royal Bank of Canada initiated coverage of Viemed Healthcare with a rating of Outperform and set a new price target of $13.00

    3/11/21 8:08:09 AM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    RBC Capital initiated coverage on Viemed Healthcare with a new price target

    RBC Capital initiated coverage of Viemed Healthcare with a rating of Outperform and set a new price target of $13.00

    3/5/21 8:11:16 AM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    $VMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Vice President of Sales Cambre Jerome converted options into 11,492 shares, covered exercise/tax liability with 2,355 shares and returned $21,490 worth of shares to the company (2,873 units at $7.48), increasing direct ownership by 6% to 104,088 units (SEC Form 4)

    4 - VIEMED HEALTHCARE, INC. (0001729149) (Issuer)

    2/2/26 5:35:27 PM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    Chief Executive Officer Hoyt Casey converted options into 53,060 shares, covered exercise/tax liability with 13,913 shares and returned $99,222 worth of shares to the company (13,265 units at $7.48), increasing direct ownership by 8% to 350,464 units (SEC Form 4)

    4 - VIEMED HEALTHCARE, INC. (0001729149) (Issuer)

    2/2/26 5:35:33 PM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    President Moore Michael converted options into 35,789 shares, covered exercise/tax liability with 7,342 shares and returned $66,924 worth of shares to the company (8,947 units at $7.48), increasing direct ownership by 11% to 189,090 units (SEC Form 4)

    4 - VIEMED HEALTHCARE, INC. (0001729149) (Issuer)

    2/2/26 5:35:21 PM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    $VMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Heltz Sabrina bought $19,977 worth of shares (2,820 units at $7.08), increasing direct ownership by 7% to 41,040 units (SEC Form 4)

    4 - VIEMED HEALTHCARE, INC. (0001729149) (Issuer)

    5/14/24 5:25:11 PM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    $VMD
    Financials

    Live finance-specific insights

    View All

    Viemed Healthcare Announces First Quarter 2025 Financial Results

    LAFAYETTE, La., May 07, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three months ended March 31, 2025, and updated guidance for the full year ending December 31, 2025. Operational highlights (all dollar amounts are USD): Net revenues for the quarter ended March 31, 2025 were $59.1 million, representing an increase of $8.5 million, or 17%, over net revenues reported for the comparable quarter ended March 31, 2024. Net income attributable to Viemed for t

    5/7/25 4:45:00 PM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    Viemed Healthcare Announces First Quarter 2025 Earnings Conference Call Details

    LAFAYETTE, La., April 22, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, today announced that it will host its First Quarter 2025 Earnings Conference Call on Thursday, May 8, 2025, at 11:00 a.m. EDT. Interested parties may participate in the call by dialing: (866) 682-6100 (US Toll-Free) +1 (862) 298-0702 (International) Live Audio Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=0dOJVhdb Following the live call, a replay will be available in the Investor Relations section of the Company's website at www.viemed.com. ABOUT VIE

    4/22/25 4:30:00 PM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    Viemed Healthcare Announces Record 2024 Financial Results

    LAFAYETTE, La., March 10, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three months and year ended December 31, 2024, and issued its guidance for the full year ending December 31, 2025. Fourth Quarter and Full Year Operational Highlights (all dollar amounts are USD): Net revenues for the quarter ended December 31, 2024 reached a new Company record of $60.7 million representing an increase of $10.0 million, or 20%, over net revenues reported for the comparable quarter ended Decembe

    3/10/25 5:00:00 PM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    $VMD
    Leadership Updates

    Live Leadership Updates

    View All

    Viemed Executes Diversification Strategy With $26 Million Acquisition of Home Equipment Provider in Illinois

    LAFAYETTE, La., May 06, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, announced that it has entered into a definitive agreement to acquire Illinois-based Lehan's Medical Equipment ("Lehan"), a healthcare company offering home medical equipment with specialties in respiratory care and women's health. "Operating for nearly 80 years, Lehan has established a well-deserved reputation for its expertise in home medical equipment with a particular emphasis on women's health and a deep commitment to community engagement," said Viemed Chief

    5/6/25 8:30:00 AM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    Viemed Announces Acquisition of Majority Interest in HomeMed, Forging Partnership With East Alabama Health

    LAFAYETTE, La., April 02, 2024 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced the finalization of its strategic partnership with East Alabama Health ("EAH"), providing Viemed with the controlling interest of East Alabama HomeMed, LLC ("HomeMed"). HomeMed provides home medical equipment services to patients within the EAH network as well as those in the surrounding areas of Eastern Alabama. "We are thrilled to join forces with the exceptional team at East Alabama Health to deliver best-in-class home medical services to their patients and expand Home

    4/2/24 9:00:00 AM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    Viemed Healthcare Announces Voting Results From Its Annual General Meeting of Shareholders

    LAFAYETTE, La., June 13, 2023 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD, TSX:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, today announced the voting results from its annual general meeting of shareholders held on June 13, 2023 (the "Meeting") in Lafayette, Louisiana. The total number of shares represented in person or by proxy at the Meeting was 27,309,147, representing 71.33% of the total issued and outstanding shares in the capital of the Company. Election of Directors The eight candidates nominated for election to the Company's Board of Directors (the "Board") and listed in the Company's m

    6/13/23 5:00:00 PM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    $VMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Viemed Healthcare Inc. (Amendment)

    SC 13D/A - VIEMED HEALTHCARE, INC. (0001729149) (Subject)

    2/15/24 9:27:58 AM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G/A filed by Viemed Healthcare Inc. (Amendment)

    SC 13G/A - VIEMED HEALTHCARE, INC. (0001729149) (Subject)

    2/15/24 9:27:32 AM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G filed by Viemed Healthcare Inc.

    SC 13G - VIEMED HEALTHCARE, INC. (0001729149) (Subject)

    2/14/24 4:51:42 PM ET
    $VMD
    Misc Health and Biotechnology Services
    Health Care